Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City-Reference-Cited by-同舟云学术

Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

Published:2021-06-12 Issue:8 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Cowman Kelsie¹^ORCID,Guo Yi²,Pirofski Liise-anne¹³,Wong David⁴,Bao Hongkai²,Chen Victor²,Hopkins Una⁵,Andrews Erin⁶,Hamel Joseph⁷,Keller Marla¹,Bellin Eran⁸,Thota Raja⁶,Davis Patricia⁵,Rodriguez Edwin Torres⁹,Suthar Pooja²,Allen Lauren²,Rossi James¹,Haviland Adam¹,Orner Erika¹⁰,Szymczak Wendy¹⁰,Shujauddin Sadahf¹¹,McCarthy James¹²,Binder Barbara¹²,Pushparaj Vanitha¹³,Bard Linda¹³,Pierino Vincent Frank¹³,Alsina Leslie¹³,Esses David¹⁴,McCaskie Alicia¹⁴,Campbell Caron¹⁴,Madzura Tabitha¹⁴,Wollowitz Andrew¹⁴,Basset Kelly¹⁴,White Deborah¹⁴,Ruiz Rafael⁶,Sosnowski Frank²,Nori Priya¹

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA

2. Department of Pharmacy, Montefiore Medical Center, Bronx, New York, USA

3. Department of Microbiology and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

4. Medical Officer, COVID-19 Therapeutics Team, US Department of Health and Human Services, Rockville, MD, USA

5. Department of Nursing, Montefiore Medical Center, Bronx, New York, USA

6. Network Performance Group, Montefiore Medical Center, Bronx, New York, USA

7. Office of Strategy, Planning, Policy and Requirements, Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC, USA

8. Department of Epidemiology, Population Health and Medicine Albert Einstein College of Medicine, Montefiore Health System, Bronx, New York, USA

9. Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA

10. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA

11. Department of Pediatric Cardiology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA

12. Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

13. Faculty Practice Group, Montefiore Health System, Bronx, New York, USA

14. Department of Emergency Medicine Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

Abstract

Abstract We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.

Funder

G. Harold and Leila Y. Mathers Foundation

National Institutes of Health

National Center for Advancing Translational Sciences

Merck

U.S. Department of Health and Human Services

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab313/38611886/ofab313.pdf